Roberto Pazo-Cid

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian, Kohei Shitara, Markus Moehler et al. · The Lancet · 2021 · 2.7K citations · Full text

Chemotherapy Versus Chemotherapy, Esophageal Cancer, Gastrointestinal Oncology +7

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang et al. · The Lancet · 2018 · 1.3K citations · Full text

Pembrolizumab Versus Paclitaxel, Gastrointestinal Oncology, Medicine +7

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Kohei Shitara, Florian Lordick, Yung‐Jue Bang et al. · The Lancet · 2023 · 609 citations

Oncology, Esophageal Cancer, Gastrointestinal Oncology +9

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols et al. · The Lancet Oncology · 2016 · 497 citations

Oncology, Tumor Heterogeneity, Unknown Primary +13

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Kohei Shitara, Jaffer A. Ajani, Markus Moehler et al. · Nature · 2022 · 415 citations · Full text